ArticleEuropean journal of neurology2026
Ten-Year Retrospective Study on the Diagnostic Value of Three-Site Skin Biopsy for Detecting pS129-α-Synuclein Biomarker: Cervical and Leg Dual-Site Biopsy as an Effective and Less Invasive Alternative.
Article in European journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe in vivo detection of phosphorylated-α-synuclein (pS129-α-syn) via immunofluorescence in cutaneous nerve fibers has emerged as a promising biomarker for diagnosing synucleinopathies, including Parkinson's disease, dementia with Lewy bodies and multiple system atrophy (MSA). However, the variability in biopsy protocols, particularly regarding the choice and number of anatomical sites, limits standardisation and clinical applicability.
objectiveTo evaluate the diagnostic accuracy of different biopsy site combinations for pS129-α-syn detection in a large cohort of patients with confirmed synucleinopathies, to identify a sampling strategy that ensures high sensitivity while reducing patient burden, promoting methodological standardisation and clinical applicability.
methodsIn this 10-year retrospective study, data from 227 patients with Lewy Body Diseases (LBD) (n = 194) or MSA (n = 33), who were identified as positive based on the three anatomical sites (two samples from each site: the cervical region (CE), thigh (TH) and distal leg (LEG)) skin biopsies protocol, were analysed. Diagnostic sensitivity was calculated for each site and combination, stratified by sex and disease duration.
resultsThe results showed that the CE + LEG combination yielded the highest diagnostic sensitivity in both the LBD (97.68%) and MSA (100%) cohorts, independent of sex and duration. The TH site offered minimal additional diagnostic value when combined with CE and LEG.
conclusionsCE + LEG dual-site skin biopsy provides high diagnostic accuracy for both LBD and MSA, making it a less invasive yet effective alternative to the tri-site protocols (six samples). The distinct deposition patterns observed between disease subtypes warrant further investigation to enhance the biomarker's diagnostic and pathophysiological relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.